What is it?
Apatone is a combination of both vitamin C and vitamin K3 that works as a treatment therapy for cancer with minimal side effects. It can be administered as a pill or an IV Infusion to prevent the growth of cancer and promote cell death. When Apatone is administered, it causes oxidative stress in tumor cells through hydrogen peroxide production. The benefit of using vitamin C and K3 is that they exhibit selective toxicity towards various strains of cancer cells. The selective nature of these vitamins allows for the protection of healthy cells while lowering the level of compounds within tumor cells that assist in energy production and protection against chemotherapy.
What has it been shown to do?
In a 2008 study, Apatone was given orally to prostate cancer patients that did not respond to standard treatment. Of the seventeen patients, thirteen showed significant positive outcomes, and fifteen patients chose to continue Apatone after the study concluded. Symptoms were reduced to mild or moderate during treatment and “many patients stated feeling better and more energetic”. The success with Apatone has also led to the production of a similar compound, BrQ, that acts in the same manner but is more efficient in hydrogen peroxide production.
Clinical trials have found cancer cells have a deficiency of alkaline and acid DNase which are activated with Apatone IV. When cancer cells are exposed to vitamin C and K3, the cell membrane splits, releasing its contents, resulting in cancer cell death through a process known as autoschizis. Additional studies have indicated that Apatone can be an effective treatment for ovarian and bladder cancer.
The discovery of homologous compounds surrounding vitamins C and vitamin K3 is ongoing and opens the door for other types of cancers to be included in treatment.
A 12 Week, Open Label, Phase I/IIa Study Using Apatone® for the Treatment of Prostate Cancer Patients Who Have Failed Standard Therapy
2-Bromo-1,4-naphthoquinone: a potentially improved substitute of menadione in Apatone™ therapy
Apatone® induces endometrioid ovarian carcinoma (MDAH 2774) cells to undergo karyolysis and cell death by autoschizis